4,901 trials
Cardiovascular Disease
Primary: Pharmacokinetics (PK): Area Under The Concentration Versus Time Curve From Time Zero To Time Tlast, Where Tlast is the Last Time Point With a Measurable Concentration…
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib (LY2484595) — 604; 597 nanograms per milliliter
Healthy Volunteers
Primary: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) — 974; 1080 nanogram.hour per milliliter (ng.h/mL)
Safety · Tolerability · Pharmacokinetics
Primary: Safety and Tolerability of AZD9567 by Assessing the Number of Participants With Adverse Events — 0; 0; 1; 0 Participants
Healthy Volunteers
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Evacetrapib — 748; 959 nanograms per milliliter (ng/mL)
Anemia
Primary: Number of Participants With Clinically Significant Events — 4; 3; 6; 5 participants
Dyslipidemia
Primary: Pharmacokinetics (PK) Parameters of Evacetrapib: Area Under the Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration…
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib — 599; 269 nanograms per milliliter (ng/mL)
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve (AUC) of LY2484595 — 12200; 17800; 17800 hours times nanograms per milliliter
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of S-Warfarin — 128; 114 nanogram*hour/milliliter (ng*h/mL)
Diabetes Mellitus, Type 2
Primary: Number of Participants With Clinically Significant Adverse Effects — 9; 8; 9; 8 Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib — 1270; 1290 nanograms/milliliter (ng/mL)
Histologically or Cytologically Confirmed Pancreatic Ca · Unresectable or Borderline Resectable Pancreatic Ca
Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants
Amnestic Mild Cognitive Impairment · Alzheimer's Disease · Prodromal Alzheimer's Disease
Primary: Area Under the Concentration Versus Time Curve of MK-8931 From 0 to Infinity (AUC0-∞) — 3.48; 3.34 micromolar(µM)*hour(hr)